A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, open-label, non-randomized study in patients with locally advanced or
metastatic breast cancer.
Each cycle will be 4 weeks in length. Patients will receive Abraxane weekly for 3 weeks.
Patients will not receive Abraxane during week 4 (rest week). Nexavar will be given
continuously.
Patients will be radiologically evaluated every 8 weeks for response. Patients will continue
to receive study treatment until disease progression or unacceptable toxicity.